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Abstract
Purpose: Pulmonary embolism (PE) is a potentially fatal cardiopulmonary disease; therefore, rapid risk stratification 
is necessary to make decisions of appropriate management strategies. The aim of this study was to assess various 
computed tomography (CT) findings in order to find new prognostic factors of adverse outcome and mortality.
Material and methods: The study enrolled 104 patients with acute PE. Based on their outcome, patients were catego-
rised into four groups. Comorbidities such as ischaemic heart disease were obtained from their medical records. 
Patients CT angiography were reviewed for recording variables such as main pulmonary artery diameter and right 
ventricle (RV)/left ventricle (LV) ratio. Patient deaths up to three months since diagnosis of PE had been registered. 
Logistic regression analysis was performed to find predictors.
Results: Based on multiple logistic regression, RV/LV ratio, LV diameter, and right-sided pulmonary infarction are 
predictors of mortality in 30 days. An RV/LV ratio of 1.19 could successfully discriminate patients who died within 
30 days and those who did not.
Conclusions: RV/LV ratio, LV diameter, right-sided pulmonary infarction, assessed with helical CT, can help predict 
30-day mortality.
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Introduction
Pulmonary embolism (PE) is a potentially fatal cardiopul-
monary disease with a mortality rate ranging from 5% to 
more than 30%, depending on the patient’s haemodynam-
ic status [1-4]. Patients with PE may have different out-
comes and therefore require varying intensities of clinical 
care. Consequently, risk assessment is necessary to make 
proper management strategy decisions [5-7]. Patients at 
high risk of adverse outcomes must be admitted to in-
tensive care units and undergo thrombolytic treatment, 
whereas hospital discharge or home treatment might 
be options for patients with a low probability of adverse 
outcomes [8,9]. Because PE may cause death after right 
ventricular failure and circulatory collapse, right ventricle 
(RV) dysfunction should be detected rapidly to identify 
patients who might benefit from fibrinolytic therapy [1]. 
Recently, computed tomography has enabled noninvasive 
PE diagnosis [10,11]. Every year, many patients undergo 
pulmonary computed tomography (CT) angiography and 
receive ionising radiation; therefore, it would be prudent 
to investigate as many CT findings as possible to identify 
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new predictors of adverse outcomes and mortality in these 
patients, to support better treatment and closer follow-up 
if needed. Some studies [7,12-15] have assessed the valid-
ity of CT scoring systems for pulmonary artery clot load, 
and others have reported RV dysfunction-related CT find-
ings [16-21]. However, few studies have investigated the 
relationships among all other CT angiography findings 
and patients’ clinical outcomes. Therefore, we conducted 
a study in patients with PE to define the prognostic value 
of CT for adverse outcomes and mortality.
Material and methods
Study population
The local Ethics Committee approved our retrospective 
study. Informed consent was waived, and patients’ data 
were reviewed from January 2015 to January 2017. The in-
clusion criteria were positive PE on CT angiography study 
and at least three months of post-diagnosis follow-up. 
The exclusion criteria were chronic pulmonary embolism, 
cardiogenic shock, and poor quality of CT images. In to-
tal 112 patients with PE were identified. We excluded six 
patients because of the poor quality of images and two pa-
tients because of cardiogenic shock; a total of 104 patients 
were enrolled in the study.
Clinical outcomes
According to the outcomes, patients were categorised into 
the following four groups: group 1 included patients who 
experienced adverse outcomes, defined as worse clinical 
conditions such as using vasopressors because of hypoten-
sion, respiratory failure, or mechanical ventilation [22,23]; 
group 2 included patients who died < 30 days after diag-
nosis of PE; group 3 included patients who died 30-90 
days after diagnosis; and group 4 included patients who 
survived and did not experience any adverse outcomes, 
denoted as the OTHERS group. In our study, we consid-
ered a patient to have died of PE-related causes if (a) the 
autopsy report, death certificate, or medical records indi-
cated PE as a cause of death or (b) shock was the leading 
cause of death in the absence of other cardiopulmonary 
diseases [24,25].
Covariate collection
Information about patients’ characteristics and comorbid-
ities were obtained from the medical records [26].
The pulmonary embolism severity index (PESI) was 
retrospectively calculated by summing the following scores: 
patient age (years), male sex (10 points), cancer (30 points), 
heart failure (10 points), chronic lung disease (10 points), 
pulse rate ≥ 110/min (20 points), systolic blood pressure 
< 100 mm Hg (30 points), respiratory rate ≥ 30/min (20 
points), temperature < 36°C (20 points), altered mental 
status (60 points), and arterial oxygen saturation < 90% 
(20 points).
Each patient’s score corresponded to the following risk 
classes: ≤ 65, class I (very low risk); 66-85, class II (low 
risk); 86-105, class III (intermediate risk); 106-125, class IV 
(high risk); and > 125, class V (very high risk) [27].
Computed tomography pulmonary angiography studies
Computed tomography pulmonary angiography (CTPA) 
examinations were conducted in the craniocaudal direc-
tion by 64-multislice CT scanners (Brilliance CT scanner, 
Philips Healthcare) at a teaching hospital. Images were 
obtained with a slice thickness of 0.9 mm, reconstructed 
at 0.5 mm slice intervals. Intravenous administration of 
120 ml of iodinated contrast medium (Visipaque 320 mg) 
was performed at 5-6 ml/s, timed by bolus tracking at 
the main pulmonary artery. The CT criterion for PE dia-
gnosis was nonocclusive thrombus (central filling defect 
outlined by the contrast agent) or occlusive thrombus in 
normal-sized or enlarged vessels [14]. A four-chambered 
heart view was used, as shown by Quiroz et al. [28]; the 
maximum transverse diameters of the right and left ven-
tricle were measured at the level of the mitral and tricuspid 
valve. The pulmonary trunk diameter was measured on 
a plane that showed the main pulmonary artery and its 
bifurcation, and the diameters of the right and left pul-
monary artery (RPA and LPA) were measured at the same 
level [29]. The diameter of the aorta was determined at the 
middle third of the ascending part. The anteroposterior 
(AP) and transverse diameters of the superior vena cava 
(SVC) were determined at the level at which the azygos 
vein entered the SVC, and the AP and transverse diameters 
of the inferior vena cava (IVC) were measured at the level 
at which the IVC joined the right atrium. We measured 
the transverse diameter of the azygos vein at the location 
where it was facing the right tracheal wall and joined the 
SVC [30]. The following observations were also recorded: 
leftward interventricular septal bowing, pleural effusion, 
and pulmonary findings, including pulmonary infarction, 
sidedness of the thrombus and level of the thrombus in the 
pulmonary artery tree. A radiologist with six years of expe-
rience in reading thoracic CT scans reported the images, 
who was blinded to the clinical history [31].
Degree of vascular obstruction
The pulmonary artery obstruction index (PAOI) was calcu-
lated by using the scoring system of Qanadli et al. [14]. We 
categorised PAOI scores into five classes: ≤ 8, class I; 8-16, 
class II; 16-24, class III; 24-32, class IV; and 32-40, class V.
Transthoracic echocardiographic evaluation
Transthoracic echocardiography, which was per-
formed within 24 hours of PE diagnosis, was used for 
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extracting information about pulmonary artery pressure 
[23,32,33].
Three-month follow-up 
All patient deaths up to three months after PE diagno-
sis were assessed by an independent committee that was 
given access to all patient data. The committee outlined 
whether a patient death should be due to PE or should be 
attributed to other causes [21].
Statistical analysis 
The Kolmogorov-Smirnov test was used for a normal 
distribution of continuous variables. Data with a normal 
distribution, such as PESI, were expressed as mean values 
with standard deviation. Parameters without normal dis-
tribution, such as age, were expressed as a median (first-
third inter-quartile range). Continuous data were com-
pared with Anova or Kruskal-Wallis tests.
Chi-square test was used for comparing discrete varia-
bles. To assess the correlation between variables, Spearman’s 
rho and Pearson’s tests were used [34]. Cut-off values for 
variables to detect mortality, determined by receiver-oper-
ating characteristic (ROC) plots and areas under the curve, 
were calculated. We also calculated the threshold value for 
which sensitivity equalled specificity for measurements 
with an Az value significantly different from 0.5 [35]. Mul-
tiple logistic regression analyses were used to identify the 
predictors of adverse outcomes by using variables p-value 
< 0.05 in univariate analysis. All statistical analyses were 
performed in SPSS version 24, SPSS Inc., Chicago, IL, USA.
Results
We included 104 consecutive patients with PE in the study. 
Patients’ demographic and clinical characteristics are 
shown in Table 1. Sixteen patients experienced adverse out-
comes. In three months, 15 deaths occurred. An independ-
ent adjudication committee concluded that all deaths could 
have been related to PE. Ten deaths occurred < 30 days after 
diagnosis, and five occurred between days 30 and 90.
The mean RV/left ventricle (LV) ratio was 1.11 (0.89-
1.39), and the death within 30 days group had the highest 
ratio (1.44 [1.16-1.68]), followed by the adverse outcome 
group (1.2 [0.95-1.61]) (p = 0.024).
The frequency of right-sided pulmonary infarc-
tion was higher among the death within 30 days group 
(5 [50%]) and adverse outcome group (5 [31%]), and 
the lowest frequency was found in the OTHERS group 
(7 [9%]) (p = 0.005).
The mean IVC AP diameter was 24 mm (21-28), and the 
adverse outcome group (20 mm [18-24]), death 30-90 days 
group (20 mm [16-29]), and death within 30 days group 
(23 mm [20-28]) had higher scores than the OTHERS group 
(25 mm [22-28]) (p = 0.017).
The azygos vein diameter was higher in the OTHERS 
group (10 mm [8-11]), with a p-value of 0.028. The OTHERS 
group had more subsegmental artery involvement (52 
[71%]) than the adverse outcome (5 [31%]), death within 
30 days (4 [40%]), and death within 30-90 days (1 [20%]) 
groups (p = 0.003).
For the correlations between each of these three para-
meters (PAOI/PAOI class, PESI/PESI class, RV/LV, RV/LV 
class) and other variables (Table 2), Pearson’s correlation 
and Spearman’s rho test were performed. The correla-
tion coefficients were highest between RV/LV and PAOI/
PAOI class and were lower (but still significant) between 
the SVC transverse diameter and PAOI/PAOI class. We 
found a negative correlation between the LV short-axis 
and PAOI (–0.363) (p < 0.001) and a positive correlation 
between MPA diameter and PESI.
In assessing the correlation between the RV/LV and 
other variables, the analysis revealed a significant corre-
lation between leftward ventricular septal bowing and the 
RV/LV ratio. Results showed a negative correlation between 
right sidedness of thrombus and the RV/LV ratio (Table 2).
Predictors of outcomes at three months
Based on univariate logistic regression analysis, signifi-
cant baseline predictors of adverse outcome were PESI 
(OR 1.01; 95% CI: 1.00-1.03; p = 0.031), IVC AP diame-
ter (mm) (OD 1.08; 95% CI: 1-1.17; p = 0.050), and right 
sidedness of the thrombus (OR 4.68; 95% CI: 1.15-19.09; 
p = 0.031), and the RV/LV ratio was a predictor of death 
within 30 days (OR 9.2; 95% CI: 1.35-63.02; p = 0.023). 
The results showed that right-sided pulmonary infarction 
(OR 0.127; 95% CI: 0.03-0.535; p = 0.005), bilateral pulmo-
nary infarction (OR 0.241; 95% CI: 0.06-0.976; p = 0.046), 
ischaemic heart disease (IHD) (OD 0.150; 95% CI: 0.036-
0.624; p = 0.009), or heart failure (HF) (OR 0.135; 95% CI: 
0.027-0.677; p = 0.015) were associated with a decreased 
risk of death within 30 days. Again, we found that a larger 
LV short-axis diameter (OR 0.089; 95% CI: 0.797-0.993; 
p = 0.038) was associated with a decreased risk of death 
in this period. IVC transverse diameter (mm) (OR 0.786; 
95% CI: 0.630-0.981; p = 0.033) and chronic obstructive 
pulmonary disease (COPD) (OR 0.063; 95% CI: 0.008-
0.491; p = 0.008) were predictors of mortality in 30-90 
days, both of which showed a protective role against mor-
tality in this period.
PAOI did not show a significant association with any 
groups (p > 0.05). Multivariable logistic regression anal-
ysis indicated that PESI (OR 1.01; 95% CI: 1.00-1.03; 
p = 0.046) and right sidedness of the thrombus in the pul-
monary tree (OR 4.5; 95% CI: 1.01-19.96; p = 0.048) were 
predictors of adverse outcomes. Based on multiple logis-
tic regression, the RV/LV ratio (OR 11.54; 95% CI: 1.16-
114.35; p = 0.037) was a strong predictor of death within 
30 days. The results showed that a longer LV short axis 
(mm) (OR 0.813; 95% CI: 0.681-0.969; p = 0.021) or having 
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right-sided pulmonary infarction (OR 0.111; 95% CI: 
0.017-0.730; p = 0.022) was associated with a decreased risk 
of mortality within 30 days, and IVC transverse diameter 
(mm) (OR 749; 95% CI: 0.574-0.979; p = 0.034) and COPD 
(OR 0.041; 95% CI: 0.004-0.448; p = 0.009) were associated 
with decreased risk of death within 30-90 days (Table 3).
Measurable variables, such as pulmonary artery pres-
sure (PAP), PESI, and main pulmonary artery (MPA) 
diameter, were tested for their ability to predict survival. 
Az was significantly higher than 0.5 for PESI (Az = 0.667), 
MPA diameter (Az = 0.663), LPA diameter (Az = 0.683), 
and aorta diameter (Az = 0.639) (p = 0.035, 0.039, 0.021, 
and 0.014, respectively). We also detected an Az value of 
0.744 and p = 0.011 for the RV/LV ratio in the death with-
in 30 days group (Table 4). For the factors which Az was 
significantly higher than 0.5, Table 4 lists the threshold 
values for which the sensitivity equalled the specificity. 
Discussion
The study investigated the prognostic value of pulmo-
nary CT angiography findings in patients with symptomatic 
PE. Below, we discuss our findings separately based on the 
variables that correlated with mortality or adverse outcomes.
Table 1. Comparisons of quantitative and qualitative characteristics of patients with pulmonary embolism between subgroups of mortality and adverse 
outcome
Object All patients 
n = 104
Adverse outcome
n = 16
Death < 30 days
n = 10
Death 30-90 days
n = 5
Others
n = 73
p-value
Age, years, median  
(25-75th percentiles)
62.5 (48-74) 54 (50-64) 71 (63-78) 65 (47-76) 62 (46-75) 0.200
Male gender 52 (50%) 7 (43%) 4 (40%) 4 (80%) 37 (50%) 0.482
PESI 92 ± 28 109 ± 34 94 ± 15 95 ± 8 88 ± 28 0.057
PAOI 10 (3-20) 10 (4-23) 15 (9-26) 11 (5-17) 8 (3-19) 0.247
MPA diameter (mm) 29.4 ± 3.8 31.5 ± 4.1 26.5 ± 3.1 26.6 ± 2.7 29.6 ± 3.6 0.003
RPA diameter (mm) 22 (20-23) 23 (21-24) 20 (18-21) 21 (19-22) 22 (20-24) 0.056
LPA diameter (mm) 21 (19-23) 22 (20-26) 20 (18-22) 20 (18-22) 21 (19-23) 0.087
Aorta diameter (mm) 32.8 ± 4.2 35.4 ± 3.6 33.4 ± 3.9 31.8 ± 2.7 32.3 ± 4.3 0.058
MPA/aorta ratio 0.9 ± 0.13 0.89 ± 0.10 0.80 ± 0.12 0.84 ± 0.13 0.92 ± 0.14 0.039
RV short axis (mm) 42.6 ± 8.85 44.33 ± 6.59 45.15 ± 8.89 41.86 ± 7.22 42.01 ± 9.40 0.625
LV short axis (mm) 38.19 ± 7.70 37.21 ± 6.98 32.96 ± 6.48 43.08 ± 3.37 38.79 ± 7.93 0.06
RV/LV ratio 1.11 (0.89-1.39) 1.2 (0.95-1.61) 1.44 (1.16-1.68) 0.88 (0.83-1.17) 1.03 (0.88-1.35) 0.024
SVC AP diameter (mm) 22.52 ± 4.41 21.53 ± 2.75 23.10 ± 5.97 22.76 ± 3.04 22.65 ± 4.58 0.793
IVC AP diameter (mm) 24 (21-28) 20 (18-24) 23 (20-28) 20 (16-29) 25 (22-28) 0.017
Azygos vein diameter 9.6 (8-11) 9.1 (8.27-11.5) 7.6 (6.37-10.22) 8 (6.5-8.9) 10 (8-11) 0.028
Right sided pulmonary infarction 18 (17%) 5 (31%) 5 (50%) 1 (20%) 7 (9%) 0.005
Left sided pulmonary infarction 11 (10%) 1 (6%) 1 (10%) 1 (20%) 8 (10%) 0.849
Sidedness of thrombose
Right 95 (91%) 16 (100%) 10 (100%) 4 (80%) 65 (89%) 0.288
Left 92 (88%) 13 (81%) 10 (100%) 4 (80%) 65 (89%) 0.476
Level of thrombose
MPA 3 (2%) 0 (0%) 0 (0%) 0 (0%) 3 (4%) 0.726
RPA 15 (14%) 1 (6%) 2 (20%) 0 (0%) 12 (16%) 0.532
LPA 11 (10%) 2 (12%) 2 (20%) 0 (0%) 7 (9%) 0.644
Lobar artery 61 (58%) 10 (62%) 9 (90%) 4 (80%) 38 (52%) 0.094
Segmental artery 88 (84%) 13 (81%) 10 (100%) 5 (100%) 60 (82%) 0.362
Subsegmental artery 62 (59%) 5 (31%) 4 (40%) 1 (20%) 52 (71%) 0.003
PAP 35 (31-50) 33.5 (25-57) 45.5 (34.5-60) 31 (24-52) 37 (32-50) 0.153
PESI – pulmonary embolism severity index, PAOI – pulmonary artery obstruction index, MPA – main pulmonary artery, RPA – right pulmonary artery, LPA – left pulmonary artery, RV – right 
ventricle, LV – left ventricle, SVC – superior vena cava, IVC – inferior vena cava, PAP – pulmonary artery pressure
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Main pulmonary artery diameter (mm) 
Our study showed that the maximum MPA diameter (31.5 
± 4.1) in the adverse outcome group was significantly 
meaningful, a finding similar to the study performed by 
Ilker et al. [29] (31.3, 95% CI: 24.3-46.4) in patients who 
experienced adverse outcomes; however, their findings 
did not reach significance (p = 0.209). In another study 
done by Lyhne et al. [7], increased diameter of the MPA 
(OR = 1.08 per 1 mm increase, p = 0.047) was associated 
with severe adverse outcome. Collomb et al. [16] found 
that patients with severe pulmonary embolism have larger 
central pulmonary artery diameters than those in other 
patients; we had similar findings. According to the study 
done by Beenen et al. [6], MPA enlargement was signifi-
cantly associated with mortality in both the short and long 
term (OR 4.18 [95% CI: 1.04-16.76] at 1 week to OR 2.33 
[95% CI: 1.36-3.97] after one year).
Table 2. Correlation between pulmonary artery clot load, pulmonary embolism severity index, right ventricle/left ventricle, and other quantitative and 
qualitive computed tomography findings
Measurement and CT scan 
findings
PAOI/PAOI class
Correlation 
coefficient
p-value PESI/PESI class
Correlation 
coefficient
p-value RV/LV, RV/LV class 
Correlation 
coefficient
p-value
PESI 0.149 0.131 – – 0.337 < 0.001
PAOI – – 0.149 0.131 0.548 < 0.001
MPA diameter (mm) 0.043 0.667 0.404 < 0.001 0.204 0.038
RPA diameter (mm) –0.042 0.673 0.499 < 0.001 22 (20-24) 0.056
LPA diameter (mm) 0.066 0.507 0.469 < 0.001 21 (19-23) 0.087
Aorta diameter (mm) 0.000 0.996 0.361 < 0.001 0.158 0.109
MPA/Aorta ratio 0.040 0.683 0.044 0.657 0.028 0.777
RV short axis (mm) 0.426 < 0.001 0.369 < 0.001 – –
LV short axis (mm) –0.363 < 0.001 –0.084 0.397 – –
RV/LV ratio 0.548 < 0.001 0.337 < 0.001 – –
SVC transverse diameter (mm) 0.206 0.036 0.353 < 0.001 0.300 0.002
IVC AP diameter (mm) –0.130 0.188 0.193 0.049 –0.122 0.217
IVC transverse diameter (mm) 0.010 0.920 0.265 0.007 0.244 0.012
Leftward ventricular septal bowing –0.124 0.210 0.198 0.044 0.433 < 0.001
Reflux into inferior vena cava –0.158 0.109 0.194 0.048 0.170 0.085
Right-sided pleural effusion –0.120 0.224 –0.040 0.688 –0.072 0.466
Left-sided pleural effusion –0.133 0.179 0.095 0.336 –0.071 0.474
Bilateral pleural effusion –0.025 0.805 0.095 0.339 –0.232 0.018
Right-sided MGG opacity 0.055 0.579 0.040 0.689 –0.153 0.121
Left-sided MGG opacity –0.154 0.119 0.203 0.039 –0.031 0.754
Sidedness of thrombose
Right 0.049 0.619 0.020 0.841 –0.348 < 0.001
left 0.095 0.335 –0.009 0.925 0.079 0.423
Level of thrombose
MPA 0.012 0.903 –0.008 0.937 0.260 0.008
RPA –0.081 0.414 0.021 0.835 0.258 0.008
LPA –0.002 0.987 0.024 0.808 0.259 0.008
Lobar artery 0.089 0.369 0.156 0.113 0.368 < 0.001
Segmental artery 0.069 0.483 0.089 0.369 0.261 0.007
Subsegmental artery 0.062 0.531 –0.089 0.371 –0.303 0.002
PAP 0.306 0.002 0.247 0.011 0.194 0.049
CT – computed tomography, PESI – pulmonary embolism severity index, PAOI – pulmonary artery obstruction index, MPA – main pulmonary artery, RPA – right pulmonary artery, LPA – left 
pulmonary artery, RV – right ventricle, LV – left ventricle, SVC – superior vena cava, IVC – inferior vena cava, PAP – pulmonary artery pressure
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Table 3. Predictors of adverse outcome and mortality in 30 days and 30-90 days of 104 patients with acute pulmonary embolism
Risk factor Adverse outcome
Univariable 
analysis
OR (95% CI)
p-value
Multivariable 
analysis
OR (95% CI) 
p-value
Death < 30 days
Univariable 
analysis
OR (95% CI)
p-value
Multivariable 
analysis***
OR (95% CI)
p-value
Death 30-90 days
Univariable 
analysis
OR (95% CI)
p-value
Multivariable 
analysis
OR (95% CI)
p-value
Age, per year 1 (0.97-1.03)
0.873
– 1.04 (0.995-1.102)
0.076
– 0.997 (0.945-1.05)
0.919
–
Male gender 0.9 (0.36-2.21)
0.819
– 2.1 (0.503-9.02)
0.304
– 0.235 (0.025-2.18)
0.203
–
PESI 1.01 (1-1.03)
0.031
1.01 (1-1.03)
0.046
0.998 (0.974-1.02)
0.885
– 1.00 (0.973-1.03)
0.804
–
PAOI 1.01 (0.96-1.06)
0.694
– 1.07 (0.996-1.16)
0.062
– 0.992 (0.892-1.1)
0.888
–
MPA diameter 
(mm)
0.994 (0.88-1.11)
0.922
– 0.824 (0.678-1)
0.051
– 0.809 (0.627-1.04)
0.104
–
RPA diameter 
(mm)
1.08 (0.95-1.22)
0.201
– 0.844 (0.676-1.05)
0.133
– 0.884 (0.669-1.16)
0.387
–
LPA diameter 
(mm)
1.03 (0.908-1.18)
0.585
– 0.887 (0.710-1.107)
0.288
– 0.924 (0.696-1.228)
0.587
–
Aorta diameter 
(mm)
1 (0.90-1.11)
0.980
– 0.980 (0.834-1.152)
0.809
– 0.939 (0.759-1.16)
0.563
–
MPA/aorta 
ratio
0.984 (0.038-25.53)
0.992
– 0.012 (0.00-2.39)
0.102
– 0.033 (0.00-26.63)
0.318
–
RV short axis 
(mm)
1.02 (0.972-1.07)
0.388
– 1.04 (0.967-1.12)
0.280
– 0.989 (0.892-1.09)
0.834
–
LV short axis 
(mm)
1.00 (0.95-1.07)
0.753
– 0.89 (0.797-0.993)
0.038
0.813 (0.681-0.969)
0.021*
1.08 (0.969-1.21)
0.153
–
RV/LV ratio 1.31 (0.35-4.9)
0.679
– 9.2 (1.35-63.02)
0.023
11.54 (1.16-114.35)
0.037**
0.109 (0.003-3.92)
0.226
–
IVC AP 
diameter (mm)
1.08 (1-1.17)
0.050
1.05 (0.96-1.15)
0.262
0.965 (0.843-1.105)
0.608
– 0.884 (0.717-1.08)
0.244
–
IVC transverse 
diameter (mm)
0.971(0.894-1.05)
0.479
– 0.943 (0.827-1.075)
0.379
– 0.786 (0.630-0.981)
0.033
0.749 (0.574-0.979) 
0.034
Right-sided 
pulmonary 
infarction
2.9 (0.62-13.7)
0.174
– 0.127 (0.03-0.535)
0.005
0.111 (0.017-0.730)
0.022*
0.164 (0.031-0.877)
0.035**
0.829 (0.087-7.88)
0.871
–
Left-sided 
pulmonary 
infarction
1.4 (0.29-7.34)
0.633
– 0.941 (0.106-8.323)
0.957
– 0.449 (0.046-4.42)
0.493
–
Sidedness 
of thrombose
Right 4.68 (1.15-19.09)
0.031 
4.5 (1.01-19.96)
0.048
– – 2.8 (0.283-28.57)
0.375
–
Left 0.60 (0.12-2.94)
0.529
– – – 0.5 (0.051-4.88)
0.551
–
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Risk factor Adverse outcome
Univariable 
analysis
OR (95% CI)
p-value
Multivariable 
analysis
OR (95% CI) 
p-value
Death < 30 days
Univariable 
analysis
OR (95% CI)
p-value
Multivariable 
analysis***
OR (95% CI)
p-value
Death 30-90 days
Univariable 
analysis
OR (95% CI)
p-value
Multivariable 
analysis
OR (95% CI)
p-value
Level of 
thrombose
MPA 0.623 (0.05-7.17)
0.705
– – – – –
RPA 0.407 (0.129-1.28)
0.126
– 0.555 (0.104-2.96)
0.491
– – –
LPA 0.826 (0.202-3.38)
0.791
– 0.366 (0.066-2.03)
0.251
– – –
IHD 0.93 (0.303-2.90)
0.911
– 0.150 (0.036-0.624)
0.009
0.310 (0.05-1.928)
0.209 *
0.300 (0.052-1.71)
0.176**
0.950 (0.1-8.99)
0.964
–
HF 2.7 (0.321-22.75)
0.360
– 0.135 (0.027-0.677)
0.015
0.161 (0.013-2.04)
0.159*
0.314 (0.031-3194)
0.328**
0.35 (0.035-3.53)
0.375
–
COPD 0.613 (0.105-3.56)
0.586
– – – 0.063 (0.008-0.491)
0.008
0.041 (0.004-0.448)
0.009
***Only variables found to significantly predict adverse outcome or mortality in 90 days by univariable analysis were entered in the multivariable model. 
Two multivariable logistic regression models are used for the variables that are significantly meaningful in univariable analysis for death < 30 days group, the first one that is shown by * includes right- 
sided pulmonary infarction, LV short axis (mm), IHD, and HF. The second one ** includes RV/LV, right-sided pulmonary infarction, IHD, and HF. 
PESI – pulmonary embolism severity index, PAOI – pulmonary artery obstruction index, MPA – main pulmonary artery, RPA – right pulmonary artery, LPA – left pulmonary artery, RV – right ventricle, 
LV – left ventricle, SVC – superior vena cava, IVC – inferior vena cava, PAP – pulmonary artery pressure, IHD – ischaemic heart disease, HF – heart failure, COPD – chronic obstructive pulmonary disease
Our findings indicate a strong positive correlation be-
tween MPA diameter and PESI, but we did not observe 
a relationship between MPA diameter and PAOI, a find-
ing that has been previously reported [30]. ROC analy-
sis indicated that when the MPA diameter was 29.9, the 
sensitivity was equal to the specificity (i.e. 62.5%) for dis-
criminating between patients who did and did not experi-
ence adverse outcomes. A similar finding was observed in 
the previous study [18], which found that MPA diameter 
could identify patients with right ventricular dysfunction, 
with a cut-off value of 29 mm. However, our study could 
not show the MPA diameter as predictive of mortality 
within 90 days, thus confirming the findings of a previ-
ous study [31], which was unable to demonstrate that a PA 
diameter > 30 mm Hg is a predictor of mortality within 
30 days or adverse outcomes.
Main pulmonary artery/aorta ratio
This ratio significantly differed among subgroups in 
our study; the death within 30 days group had the low-
est range (0.8 ± 0.12), and the OTHERS group had the 
highest range (0.92 ± 0.14). These findings were similar 
to those from a previous study by Ilker et al. [29], which 
demonstrated that an MPA/aorta ratio of 0.78 (0.48-0.87) 
in patients with mortality within 30 days was the low-
est among the studied population, but, contrary to our 
findings, the results were not significant (p = 0.101). Our 
study did not demonstrate that the MPA/aorta ratio is 
a predictor of adverse outcomes or mortality, in accord-
ance with findings from three other studies [21,30,31] in 
which the diameter of MPA and the MPA/aorta ratio were 
not found to be indicators of the mortality or severity of 
acute PE. We did not find any correlation between MPA/
aorta and PAOI, in agreement with Ghaye et al. [30].
Right ventricle/left ventricle ratio
Patients with PE and pulmonary hypertension might 
have right ventricular enlargement, which can lead to el-
evated RV/LV ratios [23]. We found the highest ratio in 
adverse outcomes and death in the death within 30 days 
group, thereby supporting findings from previous studies 
[21,36,37] showing a correlation between the RV/LV ra-
tio and MDCT and mortality. Our study showed a strong 
positive relationship between RV/LV and PAOI along 
Table 3. Cont.
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Table 4. Performance of computed tomography and echocardiography measurements for discrimination of survivors from non-survivors (each mortality 
group), as indicated by receiver operating characteristic curves
Measurement Adverse outcome
Az value
Value*
p-value
Death < 30 days
Az value
Value
p-value
Death 30-90 days
Az value
Value
p-value
Threshold 
value**
Sensitivity nearly 
equals specificity 
(%)**
PAP 0.414
(0.233, 0.594)
0.274
0.638
(0.493, 0.782) 
0.153
0.295
(0.000, 0.591)
0.123
NA NA
PAOI 0.540
(0.384, 0.697)
0.608
0.679
(0.511, 0.847) 
0.063
0.504
(0.257, 0.752)
0.976
NA NA
PESI 0.667
(0.513, 0.820)
0.035
0.551
(0.410, 0.692) 
0.597
0.583
(0.447, 0.719)
0.533
94.5 68.8
MPA diameter (mm) 0.663
(0.510, 0.816)
0.039
0.254
(0.101, 0.408) 
0.011
0.261
(0.077, 0.444)
0.072
29.9 62.5
RPA diameter (mm) 0.652
(0.521, 0.782)
0.054
0.312
(0.161, 0.464)
0.052
0.371
(0.205, 0.537) 
0.331
NA NA
LPA diameter (mm) 0.683 
(0.540, 0.825)
0.021
0.381
(0.226, 0.536) 
0.219
0.408
(0.191, 0.625) 
0.489
20.5 75
Aorta diameter (mm) 0.693
(0.563, 0.823)
0.014
0.528
(0.353, 0.704)
0.770
0.418
(0.235, 0.602)
0.538
32.9 75
MPA/aorta ratio 0.466
(0.334, 0.599)
0.669
0.281
(0.128, 0.434)
0.023
0.310
(0.052, 0.568)
0.153
NA NA
RV short axis (mm) 0.593
(0.458, 0.728)
0.238
0.590
(0.397, 0.783)
0.351
0.459
(0.221, 0.696)
0.755
NA NA
LV short axis (mm) 0.465
(0.316, 0.614)
0.656
0.280
(0.132, 0.428)
0.023
0.719
(0.587, 0.852)
0.099
NA NA
RV/LV ratio 0.587
(0.431, 0.743)
0.270
0.744
(0.600, 0.888)
0.011
0.328
(0.132, 0.524)
0.197
1.19 80
Az values were calculated and tested for difference from 0.5. For Az values that showed difference from 0.5, threshold values were calculated for which sensitivity equalled specificity. 
*Data in parentheses are 95% confidence intervals. **NA – not applicable. 
PAP – pulmonary artery pressure, PAOI – pulmonary artery obstruction index, PESI – pulmonary embolism severity index, MPA – main pulmonary artery, RPA – right pulmonary artery,  
LPA – left pulmonary artery, RV – right ventricle, LV – left ventricle 
with RV/LV and PESI; these findings are consistent with 
those from a previous study [38] that found a moderate to 
strong correlation between RV/LV and PAOI. ROC analy-
sis indicated that an RV/LV ratio of 1.19 could success-
fully discriminate patients who die within 30 days from 
those who do not, with sensitivity equal to the specificity, 
at 80%; however, this cut-off point is different from those 
in previous studies. Quiroz et al. [39] set a cut-off point 
of 0.9, and George et al. [26] described a cut-off point of 
1 for this purpose. Moreover, our study demonstrated that 
the RV/LV ratio is a strong predictor of mortality within 
30 days, thus emphasising the benefit of calculating the 
RV/LV ratio in patients with acute PE for determining 
prognosis [38]. This finding has also been shown in previ-
ous studies [38,40].
Inferior vena cava diameter
Based on our findings, patients who experienced adverse 
outcomes or mortality within 90 days had the lowest 
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IVC AP diameters, and the IVC transverse diameter had 
a weak positive correlation with PESI and the RV/LV ra-
tio. Any increase in IVC transverse diameter was associ-
ated with a lower probability of death in 30-90 days. These 
results should be investigated in future larger trials.
Right-sided pulmonary infarction
Pulmonary infarction has been reported to be associated 
with a lower mortality rate [40,41]. Similarly, our results 
showed that right-sided pulmonary infarction (RSPI) de-
creased the mortality within 30 days in patients with PE. In 
accordance with findings from previous studies [30,31,38], 
we did not find that pulmonary infarction was a predictor 
of adverse outcome and mortality within 90 days.
Pulmonary embolism severity index
We found a moderate positive correlation between PESI 
and the RV/LV ratio. According to our findings with 
a cut-off point of 94.5, PESI successfully discriminated 
patients with and without adverse outcomes, with sensi-
tivity equal to the specificity, at 68.8%.
We showed that PESI could be used as a predictor of 
adverse outcomes, in agreement with the findings of Choi 
et al. [27], in which PESI, NT-Pro BNP, and troponin were 
demonstrated to be prognostic factors of adverse outcomes.
Pulmonary artery obstruction index
We did not find any meaningful differences in PAOI 
among the groups, and our results indicate that PAOI 
cannot be used to predict mortality or adverse outcomes. 
However, our findings show a strong positive correlation 
between PAOI and the RV/LV ratio.
Aorta, right pulmonary artery, and left pulmonary artery 
diameter
Our results showed that RPA, LPA, and aorta diame-
ter had strong, strong, and moderate positive correla-
tions, respectively, with PESI. With the cut-off points of 
20.5 mm for LPA diameter and 32.9 mm for aorta diame-
ter, we were able to discriminate patients with and without 
adverse outcomes, with sensitivity equal to the specificity 
of 75%. According to previous studies [30], the aorta di-
ameter is higher in non-survivors than in survivors (36.1 
± 4.5); these findings were similar to ours, in which the 
aorta diameters in the adverse outcome group (35.4 ± 3.6) 
and the mortality within 30 days group (33.4 ± 3.9) were 
higher than those in the remaining groups.
Right ventricle and left ventricle diameter
PE, along with pulmonary hypertension, may cause right 
ventricular enlargement. Our study showed that the RV 
and LV short-axis diameters did not differ among groups. 
Oz et al. [29] have reported similar findings, in which 
the LV diameter was not found to differ among patients 
with and without adverse clinical outcomes, and among 
patients who did and did not die within 30 days; however, 
there was a difference in RV diameter between patients 
with and without adverse clinical outcomes (p = 0.001).
According to our analysis, RV diameter has a strong 
positive correlation with PAOI, similarly to the findings 
of a previous study [30]. Moreover, there was a moder-
ate positive correlation between RV diameter and PESI. 
Our results showed that any increase in PAOI makes the 
LV diameter decrease, in accordance with findings from 
a previous study [30] reporting a robust negative correla-
tion between LV diameter and PAOI.
Our study demonstrated that any decrease in LV dia-
meter increases the probability of death within 30 days 
and, therefore, might be used as a predictor of mortality.
Superior vena cava transverse diameter
Our study showed a weak positive correlation between 
SVC transverse diameter and PAOI, similar to the find-
ings of a previous study [30] that did not show such a re-
lation.
We also found a moderate positive correlation be-
tween SVC transverse diameter and PESI and the RV/LV 
ratio. In our analysis, the differences in the diameter of 
SVC among subgroups were not significantly meaningful, 
but Ghaye et al. [30] demonstrated that mean SVC diame-
ter in non-survivors is higher than that in survivors; also, 
Ghuysen et al. [28] found a significant correlation of SVC 
diameter with mortality.
Right sidedness of thrombus
According to our findings, there was a moderate nega-
tive correlation between right sidedness of the thrombus 
and the RV/LV ratio: right sidedness of the thrombus was 
correlated with a lower RV/LV ratio and was found to be 
a predictor of adverse outcomes.
Chronic obstructive pulmonary disease
We found that patients with COPD were less likely to die 
in the 30 to 90-day period, a new finding not reported in 
previous studies [23,34,42].
Limitations
The present study also has some limitations. First, our 
PAOI (median 10.5, range 4-20) was relatively low. Sec-
ond, the potential effects of PE-specific therapy on clinical 
outcomes were not considered. Third, the small group size 
(death < 30 days; death 30-90 days; adverse outcome) may 
bias the results.
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Conclusions
Our study is the first attempting to find correlations 
between various CT findings and adverse outcomes or 
mortality within 90 days in four subgroups of patients 
with PE. We determined that RV/LV, LV diameter, and 
right-sided pulmonary infarction are predictors of mor-
tality within 30 days, and IVC diameter and COPD have 
prognostic value in determining mortality in the 30 to 
90-day period. We also found that PESI and right sided-
ness of the thrombus are predictors of adverse outcomes. 
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